4D Molecular Therapeutics, Inc. financial data

Symbol
FDMT on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
5858 Horton Street #455, Emeryville, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.15K % +16.4%
Debt-to-equity 7.19 % -27.1%
Return On Equity -28.6 % +16.3%
Return On Assets -26.7 % +14.2%
Operating Margin -508K % -93113%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49.8M shares +49.8%
Common Stock, Shares, Outstanding 45.8M shares +6.31%
Entity Public Float 1.04B USD +65.7%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 53.9M shares +37.9%
Weighted Average Number of Shares Outstanding, Diluted 53.9M shares +37.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 37K USD -99.8%
Revenue from Contract with Customer, Excluding Assessed Tax 37K USD -99.8%
General and Administrative Expense 46.6M USD +27.6%
Operating Income (Loss) -188M USD -66.4%
Nonoperating Income (Expense) 27M USD +124%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -161M USD -59.5%
Earnings Per Share, Basic -2.98 USD/shares -15.5%
Earnings Per Share, Diluted -2.98 USD/shares -15.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 149M USD -40.1%
Marketable Securities, Current 276M USD +604%
Assets, Current 435M USD +46.6%
Property, Plant and Equipment, Net 19.5M USD -2.94%
Operating Lease, Right-of-Use Asset 21.1M USD +82.6%
Other Assets, Noncurrent 4.26M USD +523%
Assets 560M USD +64.9%
Accounts Payable, Current 4.39M USD +24.8%
Employee-related Liabilities, Current 8.11M USD -0.53%
Accrued Liabilities, Current 18.9M USD +57.1%
Contract with Customer, Liability, Current 257K USD -5.86%
Liabilities, Current 29.1M USD +53.8%
Contract with Customer, Liability, Noncurrent 1.06M USD +8.75%
Operating Lease, Liability, Noncurrent 19M USD +64.6%
Other Liabilities, Noncurrent 193K USD -22.2%
Liabilities 49.8M USD +55.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 229K USD +1331%
Retained Earnings (Accumulated Deficit) -576M USD -38.7%
Stockholders' Equity Attributable to Parent 511M USD +65.9%
Liabilities and Equity 560M USD +64.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -29.1M USD -4.24%
Net Cash Provided by (Used in) Financing Activities 319M USD +2800%
Net Cash Provided by (Used in) Investing Activities -263M USD -710%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 45.8M shares +6.31%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 26.5M USD +1.02%
Deferred Tax Assets, Valuation Allowance 128M USD +8.98%
Deferred Tax Assets, Gross 134M USD +9.08%
Operating Lease, Liability 24.6M USD +67.7%
Depreciation 4.8M USD +9.09%
Payments to Acquire Property, Plant, and Equipment 710K USD -29.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -161M USD -61.3%
Lessee, Operating Lease, Liability, to be Paid 33.2M USD +82.4%
Property, Plant and Equipment, Gross 36.1M USD +12.7%
Operating Lease, Liability, Current 5.64M USD +79%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.6M USD +72.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.64M USD +79%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +38.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 8.62M USD +143%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.35M USD +70.7%
Deferred Tax Assets, Operating Loss Carryforwards 72.4M USD +21.6%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 7.08M USD -40.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.51M USD +96.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 26.1M USD +32.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%